Source - LSE Regulatory
RNS Number : 5948Q
e-Therapeutics plc
01 March 2021
 

 

e-therapeutics plc

("e-therapeutics" or the "Company")

Change of Adviser

 

Oxford, UK, 1 March 2021 - e-therapeutics plc (AIM: ETX) is pleased to announce the appointment of SP Angel Corporate Finance LLP as the Company's Nominated Adviser and Broker, with immediate effect.

Director Disclosure

The Company also announces the following additional information in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies in respect of Ali Mortazavi, CEO of the Company. Mr Mortazavi is a current LLP Member of Arcade Films 4 LLP and was at the time of his appointment to the Board on 11 February 2020.

 

Enquiries:

e-therapeutics plc

 

Ali Mortazavi, CEO

Tel: +44 (0)1993 883 125

 

www.etherapeutics.co.uk

 

 

SP Angel Corporate Finance LLP

Tel: +44(0)20 3470 0470

Nominated Adviser and Broker

 

Matthew Johnson/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

 

 

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPBQLLLFLLXBBV
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.